WhiteCoat
Singapore telemedicine and virtual clinic operator with insurance-backed distribution.
On the record
Checkpoint: Resolution of Vietnam genetic-test falsification probe and AIA contract renewal terms
The call
WhiteCoat still holds its insurance pipeline and regulatory head start, but a richer rival and an unresolved trust probe are closing in at the same time.
WhiteCoat provides online doctor visits and prescriptions in Malaysia and nearby countries. It has real advantages: a deal giving it access to over 1 million people through AIA insurance, and a government license to prescribe. But these advantages are fragile. Doctor Anywhere is a direct competitor that has raised 15 times more money ($176M versus WhiteCoat's $8-11.7M), has the same government license, and operates in the same region. AI chatbots like SymptomAI are also taking away customers who might have used WhiteCoat first. WhiteCoat was also hit by a trust problem in April 2025 when it falsified genetic test reports. The one thing that could save WhiteCoat: if Doctor Anywhere stumbles or moves to a different region, giving WhiteCoat room to grow without constant outspending.
Why
01
AI pressure: AI symptom checkers and triage tools like Google SymptomAI and Infermedica. AI triage tools could grab patients before they ever open WhiteCoat's app, cutting into the top of its funnel. Could AI do the core job? Only partly.
02
Bigger players: Doctor Anywhere. Same license, same region, but Doctor Anywhere has raised about 15 times more capital and already covers five countries. Could a giant copy it? Yes, easily.
03
What protects it. Exclusive AIA distribution deal covering over 1 million insured members plus early MOH sandbox and Home Recovery status.
What would change this call
Whether AIA renews its exclusive WhiteCoat partnership past its current term. Loss would remove WhiteCoat's largest distribution channel of over 1M members.
Doctor Anywhere announces a new funding round or Malaysia/Thailand expansion in the next year. Would confirm the capital and geographic gap with WhiteCoat is widening.
Regulatory outcome of the April 2025 Vietnam genetic-test falsification probe. A sanction would deepen trust damage; a clean clearance would remove the overhang.
Doctor Anywhere announces a new funding round or Malaysia/Thailand expansion in the next year. Would confirm the capital and geographic gap with WhiteCoat is widening.
Regulatory outcome of the April 2025 Vietnam genetic-test falsification probe. A sanction would deepen trust damage; a clean clearance would remove the overhang.
Key numbers
- AIA exclusive deal covers over 1M insured members
- Total funding roughly $8M to $11.7M
- Doctor Anywhere raised $65.7M in one round alone
Named risks
- Unresolved Vietnam genetic-test falsification probe disclosed April 2025 could bring regulatory sanction.
- 15x funding gap versus direct rival Doctor Anywhere limits regional expansion capacity.
- Loss of Singtel distribution channel since August 2023 reduced consumer reach.
- AI symptom-checker tools (SymptomAI, Infermedica) could intercept patients before they reach WhiteCoat's funnel.
- Announced Malaysia and Thailand expansion (Nov 2024) unproven as of mid-2026.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Doctor Anywhere | losing to | Doctor Anywhere holds ~$176.4M total funding vs WhiteCoat's $8M-$11.7M as of Oct 2024 |
| Google SymptomAI | contesting | Gemini-based SymptomAI tested with ~13,917 participants through mid-2026, matching clinician performance on some triage benchmarks |
| Infermedica | contesting | Received MDR Class IIb certification in 2025, pursuing agentic AI conversational triage roadmap for 2026 |
| Fullerton Health Group | contesting | Operates 198+ clinics across 4 countries with >S$300M 2016 revenue and 2025 Mitsubishi Corp investment, a larger incumbent adjacent to telehealth |
Questions people ask
- Is WhiteCoat profitable in 2026?
- No profitability figures have been disclosed by WhiteCoat. The company is privately funded at roughly $8M-$11.7M through Series B as of October 2024, and has not released revenue or profit statements; only unverified aggregator estimates exist.
- Could AI replace WhiteCoat's telehealth app?
- AI symptom checkers like Google's SymptomAI (tested on ~13,917 people through mid-2026) and Infermedica's MDR-certified triage tool threaten WhiteCoat's front-end symptom intake, but cannot replace its MOH-licensed prescribing and Singapore-registered doctor network, which require legal medical status.
- Who is WhiteCoat's biggest competitor?
- Doctor Anywhere is WhiteCoat's closest same-model rival in Singapore telehealth. Doctor Anywhere raised $65.7M in a 2021 Series C (total funding ~$176.4M) versus WhiteCoat's $8M-$11.7M, giving it roughly 15 times more capital as of late 2024.
- Who owns WhiteCoat?
- WhiteCoat Holdings Pte Ltd is privately held and venture-backed. Its October 2024 funding round for the Good Doctor Indonesia acquisition was led by Raffles Family Office, with MDI Ventures and SoftBank Vision Fund also participating.
- Did WhiteCoat lose any major distribution partners?
- Yes. Singtel discontinued new sign-ups for the WhiteCoat TeleHealth mobile add-on from August 2023, though existing subscribers were grandfathered for 12 months, removing one of WhiteCoat's consumer distribution channels.
- What is WhiteCoat's AIA partnership worth?
- WhiteCoat has been AIA Singapore's exclusive telehealth provider since 2019. In November 2024 the partnership deepened to extend telemedicine, mental wellness, paediatric, and screening access to over 1 million AIA insured members.
Timeline
- 2025-04-25WhiteCoat discloses internal probe into ~300 falsified genetic test reports in Vietnam
- 2024-11-22WhiteCoat opens regional HQ in Singapore, announces Malaysia and Thailand expansion plans
- 2024-11-03AIA Singapore partnership deepened to cover over 1 million insured members
- 2024-10-10WhiteCoat Global announces Good Doctor Indonesia acquisition and RFO-led funding round
- 2023-08-01Singtel discontinues new sign-ups for WhiteCoat TeleHealth mobile add-on
- 2021-12-14Thomson Medical Group and WhiteCoat form Thomson X joint venture
- 2020-04-07WhiteCoat becomes first startup in MOH telemedicine regulatory sandbox and MOH Home Recovery partner
- 2019-04-15WhiteCoat becomes AIA Singapore's exclusive telehealth provider
- 2018WhiteCoat founded by CEO Bryan Koh in Singapore
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Products, Competitors, Financials, Employees, Headquarters Locations (2025-04-25)
- Valuation, Funding Rounds & Stock Price (2024-10-10)
- AIA Singapore and WhiteCoat enter landmark partnership (2019-04-15)
- AIA Singapore enhances accessibility to quality healthcare services (2024-11-03)
- WhiteCoat brings convenience to Singapore's healthcare (2020-04-07)
- Novo Holdings participates in US$65.7 Million Series C Financing (2021-08-31)
- Series C Update: Message from the CEO (2021-08-31)
- Singtel WhiteCoat TeleHealth FAQ
- WhiteCoat Global has announced that it will be acquiring Good Doctor Indonesia (2024-10-10)
- Telehealth firm WhiteCoat opens HQ in S'pore (2024-11-22)
- Towards a conversational AI agent for everyday symptom assessment (2026-07-22)
- Accuracy, HIPAA & ROI [2026] (2025-10-30)